Status:
UNKNOWN
Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy
Lead Sponsor:
Poitiers University Hospital
Conditions:
Obstructive Sleep Apnea-hypopnea
Oropharyngeal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyn...
Eligibility Criteria
Inclusion
- Age\> 18 years old
- Performance Status 0-2
- Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy
- Treatment termination time greater than 6 months at inclusion
- Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3
- Patient in complete remission at inclusion
- patient's consent's obtained after information
Exclusion
- Previous treatment for upper aerodigestive tract cancer
- Incomplete radiotherapyTreatment
- Neurological pathology wich may affect the functions of the upper aerodigestive tract
- Pregnant or breastfeeding woman
- Unweaned alcoholism
- Tracheotomized patient at the time of the study
- Patient under protection: subjects with guardianship or under law protection
- No health insurance coverage
Key Trial Info
Start Date :
July 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04440618
Start Date
July 30 2020
End Date
June 30 2021
Last Update
January 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Poitiers
Poitiers, France, 86000